|
|
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia
Salem Bahashwan
,
Cécile Moluçon-Chabrot
,
Eric Hermet
,
Aurélie Ravinet
,
Aurore Douge
et al.
Journal articles
hal-01926811v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Maladie de Gaucher
Marc Berger
4èmes Journées d’Hématologie Biologique du Grand-Est, Mar 2019, Nancy, France
Conference papers
hal-02125901v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity
Marc Berger
,
Céline Bourgne
Book sections
hal-02301455v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy
Pedro Prata
,
Matthieu Resche-Rigon
,
Didier Blaise
,
Gérard Socié
,
Pierre-Simon Rohrlich
et al.
Journal articles
hal-02301304v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Romain Guièze
,
Vivian Liu
,
Daniel Rosebrock
,
Alexis Jourdain
,
María Hernández-Sánchez
et al.
Journal articles
hal-02318784v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp Staber
,
Marco Herling
,
Mar Bellido
,
Eric Jacobsen
,
Matthew Davids
et al.
Journal articles
hal-02318820v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia
C. Kornauth
,
C. Herbaux
,
B. Boidol
,
C. Guillemette
,
P. Caron
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.3965, 2019, Blood
Conference poster
hal-02427551v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study
Karim Labreche
,
Mailys Daniau
,
Amit Sud
,
Philip J Law
,
Louis Royer-Perron
et al.
Journal articles
hal-02328989v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Quelle place pour l’allogreffe à l’ère des nouvelles drogues et des nouvelles approches d’immunothérapie dans les hémopathies malignes ? (SFGM-TC)
Jacques-Olivier Bay
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France
Conference papers
hal-02124755v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Round table : impact of CAR T-cells on patient journey, local or regional organization, and follow-up
Jacques-Olivier Bay
Cell Therapy Innovation 360°, May 2019, Lyon, France
Conference papers
hal-02056276v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Accuracy of Chitotriosidase Activity and CCL18 Concentration in Assessing Type I Gaucher Disease Severity. A Systematic Review with Meta-analysis of Individual Participant Data
Tatiana Raskovalova
,
Patrick B. Deegan
,
Pramod K. Mistry
,
Elena Pavlova
,
Ruby Yang
et al.
13th EWGGD Meeting, Jul 2019, Clermont-Ferrand, France
Conference poster
hal-02304018v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Traitement de première ligne de la Leucémie Myéloïde Chronique dans la « vraie vie » : Données de l’Observatoire LMC
Alexandre Janel
,
Sandrine Saugues
,
C. Lambert
,
Hyacinthe Johnson-Ansah
,
Denis Guyotat
et al.
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France. 25 (S1), pp.172, 2019, Hématologie
Conference poster
hal-02304921v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Arrêt des Inhibiteurs de Tyrosine Kinase (ITK) pour réponse optimale dans la LMC dans la « vraie vie » et recommandations du groupe Fi-LMC
Alexandre Janel
,
Sandrine Saugues
,
C. Lambert
,
Hyacinthe Johnson-Ansah
,
Denis Guyotat
et al.
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France. 25 (S1), pp.173, 2019, Hématologie
Conference poster
hal-02304953v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients
Loic Ysebaert
,
A.S. Michallet
,
F. Bijou
,
A. Clavert
,
A. Quinquenel
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Conference poster
hal-02427548v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma
Clémentine Sarkozy
,
Christiane Copie-Bergman
,
Diane Damotte
,
Susana Ben-Neriah
,
Barbara Burroni
et al.
Journal articles
hal-02055918v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1
Juliette Berger
,
Marie Vigan
,
Bruno Pereira
,
Thu Thuy Nguyen
,
Roseline Froissart
et al.
Journal articles
hal-02052295v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prévalence élevée des mutations de BTK chez les patients atteints de leucémie lymphoïde chronique (LLC) après 3 ans d’ibrutinib - Une étude de « vraie vie » du groupe FILO-LLC
A. Quinquenel
,
L.M. Fornecker
,
R. Letestu
,
C. Fleury
,
Loic Ysebaert
et al.
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France. pp.23
Conference papers
hal-02305156v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Untreated patients with type 1 Gaucher disease: who are they? Resultas from the Gaucher Non-Treated study (GANT study)
Christine Serratrice
,
Jérôme Stirnemann
,
Amina Berrahal
,
Nadia Belmatoug
,
Fabrice Camou
et al.
13th EWGGD Meeting, Jul 2019, Clermont-Ferrand, France
Conference papers
hal-02305170v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome
Marc Berger
,
Bruno Pereira
,
Philippe Rousselot
,
Pascale Cony‐makhoul
,
Martine Gardembas
et al.
Journal articles
hal-02345944v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Franck Emmanuel Nicolini
,
Stéphanie Dulucq
,
Lisa Boureau
,
Pascale Cony-Makhoul
,
Aude Charbonnier
et al.
Journal articles
hal-02374871v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Clinical and Biological Characteristics and Outcomes of Richter Transformation: A French Multicenter Study from the Filo Group
C. Moulin
,
R. Morizot
,
T. Remen
,
H. Augé
,
F. Bouclet
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.4112, 2019, Blood
Conference poster
hal-02427541v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
High‐dose therapy with autologous stem cells transplantation in Bing‐Neel syndrome: A retrospective analysis of 14 cases
Laurence Simon
,
Richard Lemal
,
Luc‐matthieu Fornecker
,
Olivier Tournilhac
,
Véronique Leblond
et al.
Journal articles
hal-02885345v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC
Alexis Caulier
,
Elodie Drumez
,
Jordan Gauthier
,
Marie Robin
,
Didier Blaise
et al.
Current Research in Translational Medicine, 2019, 67 (1), pp.8-15
Journal articles
hal-02055904v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Session 18 “General Session – Part I -REPEAT”
Jacques-Olivier Bay
1st European CAR T Cell Meeting, Feb 2019, Paris, France
Conference papers
hal-02125948v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
1 an après la publication des recommandations sur l’arrêt de traitement quelle est l’attitude des professionnels de santé ?
Marc Berger
Membre du board Novartis de réflexion et d’échange, Feb 2019, Paris, France
Conference papers
hal-02125982v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Richard Lemal
,
Olivier Tournilhac
Journal articles
hal-02299391v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency
Hélène Coignard-Biehler
,
Nizar Mahlaoui
,
Benoît Pilmis
,
Vincent Barlogis
,
Pauline Brosselin
et al.
Journal articles
hal-02377907v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Evolution des stratégies thérapeutiques de première ligne
Olivier Tournilhac
39e Congrès de la Société Française d’Hématologie, Mar 2019, Paris, France
Conference papers
hal-02125859v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
What did intra-cellular Pk of imiglucerase teach us?
Marc Berger
13th EWGGD Meeting, Jul 2019, Clermont-Ferrand, France
Conference papers
hal-02124741v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Gaucher disease: baseline preliminary data of the french eliglustat patient reported outcome study (ELIPRO)
Fabrice Camou
,
Francis Gaches
,
Bérengère Cador-Rousseau
,
Angela Coutinho
,
Nadia Belmatoug
et al.
13th EWGGD Meeting, Jul 2019, Clermont-Ferrand, France
Conference poster
hal-02303946v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|